Clinical trials: Histamine
Multiple Sclerosis, Relapsing-Remitting
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
This is a randomized, parallel group, placebo-controlled study designed to assess whether GSK239512 can enhance lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01772199
- Testing
- GSK239512
- Where
- 43 sites in Bulgaria, Canada and 6 more
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Hypersensitivity
The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of…
- Trial name
- NCT00359138
- Testing
- desloratadine, levocetirizine
- Volunteers
- 36 people
- Sponsor
- Organon and Co
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).
The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended
- Trial name
- NCT00917488
- Testing
- Standardization of allergenic extract (Gly. domesticus)
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy to Mites
Biological Standardization of Blomia Tropicalis Allergen Extract
The objective of this study is to determine the biologic activity of a Blomia tropicalis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01597752
- Testing
- Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy Pollen, Allergic Reaction
Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.
The objective of this study is to determine the biological activity of Juniperus oxycedrus and Cupressus arizonica. allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference…
- Conditions
- Allergy Pollen, Allergic Reaction, Allergic Skin Reaction
- Trial name
- NCT05533385
- Testing
- Allergenic extract
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Leukemia
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in…
- Trial name
- NCT00003991
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 360 people
- Sponsor
- Maxim Pharmaceuticals
Allergy to Grass Pollen
Biological Standardization of Poa Pratensis Allergen Extract
The objective of this study is to determine the biologic activity of a Poa pratensis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01430117
- Testing
- Four different concentrations of Poa pratensis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinitis, Allergic, Seasonal
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects
This study is designed to assess the safety and tolerability of single, escalating oral doses and repeat oral doses (7 days, once daily) of GSK835726 in healthy male subjects
- Trial name
- NCT00605852
- Testing
- GSK835726
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Brain Distribution of [11C]AZ12807110 and AZD5213
Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration
The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.
- Trial name
- NCT01194986
- Testing
- [11C]AZ12807110, AZD5213
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Histamine Intolerance
A Provocation Study Using Biogenic Amines to Show the Efficacy of Oral Diamine Oxidase Supplementation
This study aims to define a provocation test for histamine intolerance (aka. biogenic amine intolerance syndrome) and test the capability of an oral enzyme supplementation to ameliorate this condition.
- Trial name
- NCT02418221
- Testing
- Drawing blood, measuring BP & pulse
- Where
- Austria
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- IPSC AG
Immune System Diseases
Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts
Four concentrations of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extracts, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol…
- Trial name
- MM09 (NCT02527122)
- Testing
- Allergen extracts
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Asthma
Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8
The study focusses on the evaluation of safety and tolerability of the XC8. The design of the study involves sequential dosing of cohorts (group of volunteers), taking increasing doses of the product after receiving conclusion…
- Trial name
- NCT02882217
- Testing
- XC8 (histamine glutarimide)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- EURRUS Biotech GmbH
Asthma
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of XC8 after single and repeated oral administration in healthy volunteers.
- Trial name
- NCT03441815
- Testing
- XC8
- Where
- Russia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- PHARMENTERPRISES LLC
Allergy to Pollen
To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.
The objective of this study is to determine the biological activity of Artemisia vulgaris allergen extract in histamine equivalent units (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01984541
- Testing
- Artemisia vulgaris
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Laboratorios Leti, S.L.
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
- Trial name
- NCT03517566
- Testing
- ZPL389 3mg, ZPL389 10mg, ZPL389 30mg
- Where
- 89 sites in United States, Austria and 14 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Narcolepsy
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
This study is of an investigational drug called SUVN-G3031 (Samelisant) as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy.
- Trial name
- SUVN-G3031 (NCT04072380)
- Testing
- SUVN-G3031
- Where
- 41 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Suven Life Sciences Limited
Idiopathic Hypersomnia
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in participants with idiopathic hypersomnia (IH) age ≥18 years.
- Trial name
- NCT05156047
- Testing
- Open-label Pitolisant, Double-blind Pitolisant
- Where
- 58 sites in United States
- Volunteers
- 214 people
- Sponsor
- Harmony Biosciences Management, Inc.
Rhinitis, Allergic, Perennial
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.
- Trial name
- NCT00490204
- Testing
- Cetirizine
- Where
- 28 sites in Japan
- Volunteers
- 239 people
- Sponsor
- GlaxoSmithKline
Food Intolerance, Histamine Intolerance
Study to Investigate the Effect of an Oral Diamine Oxidase Substitution (DAOsin) in Histamine Intolerant Patients on the Low Endogenous Diamine Oxidase Serum Activity
DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake. In this uncontrolled, interventional pilot study the effect of an oral diamine oxidase substitution…
- Trial name
- NCT03298568
- Testing
- DAOsin
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Sciotec Diagnostic Technologies GmbH
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.